Minnesota Controlled Substance Prescribing Laws and Penalties

To prescribe controlled substances legally in Minnesota, every prescription you write must serve a legitimate medical purpose within a genuine patient-practitioner relationship, and you must satisfy a stack of specific obligations that sit on top of that baseline: opioid dosage limits, a mandatory query of the state Prescription Monitoring Program before the first opioid script, a current DEA registration paired with one-time MATE Act training, and documentation strong enough to defend later. Minnesota controlled substance prescribing laws live primarily in Chapter 152 of the state statutes, and they apply to physicians, nurse practitioners, physician assistants, dentists, and every other authorized prescriber in the state.¹

The Two Threshold Requirements

Every controlled substance prescription in Minnesota has to clear two gates. The prescription serves a legitimate medical purpose. And the prescriber has an established relationship with the patient, meaning a personal evaluation, a review of the patient’s medical history, and documented clinical reasoning for the drug chosen.¹ Writing a controlled substance prescription for someone you have not examined is exactly the conduct that triggers board investigations.

Before reaching for an opioid, prescribers are expected to consider non-opioid pain management options and, when opioids are warranted, use the lowest effective dose.² Jumping to a high-dose opioid without documenting why alternatives were inadequate is a pattern that draws attention from both the Board of Medical Practice and malpractice plaintiffs. Patients also need to understand the risks of what they are receiving: physical dependence, impaired driving, and the danger of combining opioids with benzodiazepines or alcohol.

Opioid Dosage Limits

Minnesota’s opioid prescribing guidelines set concrete numbers rather than vague cautions. For acute pain, prescribers should avoid writing for more than a three-day supply, or 20 pills, of low-dose, short-acting opioids. Even when circumstances justify more, an initial acute prescription should not exceed seven days or roughly 200 morphine milligram equivalents.³ Shorter initial courses mean fewer leftover pills, and lower total doses reduce the chance that acute pain treatment turns into long-term dependence.

The CDC’s 2022 Clinical Practice Guideline, which Minnesota’s approach aligns with, recommends starting opioid-naïve patients at roughly 5 to 10 MME per single dose, or 20 to 30 MME per day. Clinicians should reassess carefully before pushing total daily dosage to 50 MME or above, and patients at that level warrant closer follow-up.⁴ These are not hard legal caps. But a prescriber who routinely exceeds them without clear documentation will have trouble defending the pattern.

For patients on long-term opioid therapy, a written treatment agreement is not required by Minnesota statute, but it is powerful documentation. A useful agreement identifies the diagnosis, spells out side effects and drug-interaction risks, distinguishes physical dependence from addiction, commits the patient to a single prescriber and pharmacy, and sets functional treatment goals with a plan for tapering if those goals are not met.

The Prescription Monitoring Program Query

Minnesota’s Prescription Monitoring Program, established under Section 152.126, is a statewide database that tracks every dispensed controlled substance prescription. Pharmacies and office-dispensing prescribers submit data covering Schedules II through V, plus butalbital and gabapentin, and the Board of Pharmacy administers the system.⁵ Each record shows the patient, prescriber, drug, and quantity, which lets clinicians catch overlapping opioid prescriptions from multiple providers, escalating quantities, or a dangerous opioid-benzodiazepine combination before filling.

Since January 1, 2021, Minnesota clinicians have been required to query the PMP before writing an initial prescription for Schedule II through IV opioids. This is not optional. Skipping the PMP check before that first opioid script is a compliance violation, full stop. Many health systems have integrated PMP access into their EHRs, sometimes with automated alerts for patients with multiple recent opioid prescriptions, which makes the check nearly frictionless where it exists.

Access is restricted to Minnesota-licensed prescribers, pharmacists, and their authorized delegates, and the data is treated as protected health information. Law enforcement cannot browse the database on a hunch; the system is a clinical decision-making tool first.⁵

DEA Registration and MATE Act Training

Every prescriber writing controlled substance prescriptions in Minnesota needs a current DEA registration, which runs on a three-year cycle. The registration authorizes specific schedules, and prescribing outside your authorized schedules is a serious violation.

Since June 27, 2023, all DEA-registered practitioners (except those who exclusively treat animals) must also complete a one-time, eight-hour training on treating and managing patients with opioid or other substance use disorders. The requirement comes from the Mainstreaming Addiction Treatment (MATE) Act, embedded in the Consolidated Appropriations Act, and practitioners attest to meeting it when they apply for a new registration or renew an existing one.⁶

The eight hours can be accumulated over time rather than done in one sitting, and once you have attested you do not need to repeat it at future renewals. Failing to complete the training before your next registration submission lets the DEA refuse to process the application, which effectively blocks your ability to prescribe until you comply.⁶

Minnesota also requires healthcare providers to complete continuing education related to controlled substances as part of each licensure renewal cycle. The specific hour requirements vary by license type and board, and these state CE requirements are recurring, separate from the one-time MATE attestation.

Telehealth Prescribing Through 2026

Prescribing controlled substances by telehealth normally requires at least one prior in-person evaluation under the federal Ryan Haight Act. A series of temporary extensions that began during the COVID-19 pandemic continues to waive that requirement. The DEA’s Fourth Temporary Rule, effective January 1, 2026, through December 31, 2026, allows DEA-registered practitioners to prescribe Schedule II through V controlled substances via telehealth without an in-person visit, provided the prescription is issued in the usual course of professional practice, the visit uses real-time audio-visual communication, the prescriber’s DEA registration covers the schedule involved, and all normal documentation and PMP obligations are met.⁷

This is temporary. The DEA has not finalized permanent telehealth prescribing regulations, so when the extension expires the in-person evaluation requirement snaps back into effect unless permanent rules are in place. Anyone building a practice around telehealth controlled substance prescribing should track federal rulemaking closely.

Penalties for Non-Compliance

The consequences of violating Minnesota’s controlled substance prescribing rules stack, and they can hit from four directions at once.

State Licensing Actions

The Minnesota Board of Pharmacy can refuse to renew, suspend, condition, limit, or qualify the license of any prescriber or pharmacist who fails to comply with controlled substance regulations.⁸ The Board of Medical Practice has similar authority over physicians. Actions range from a letter of reprimand for minor documentation lapses to full license revocation for egregious prescribing patterns.

Criminal Prosecution

Improper prescribing can rise to criminal conduct under Minnesota law. Prescribers who write controlled substance prescriptions outside the bounds of legitimate medical practice face potential felony charges, with imprisonment and fines. A prescriber running a pill mill faces far harsher exposure than one who made a borderline judgment call on a legitimate patient’s dosage.

Federal Program Exclusion

For prescribers who bill Medicare, Medicaid, or other federal health programs, the exposure runs beyond state licensing. The U.S. Department of Health and Human Services Office of Inspector General is required by law to exclude any individual with a felony conviction related to unlawful prescribing or dispensing of controlled substances from all federal health care programs. Even a misdemeanor controlled substance conviction gives the OIG discretion to impose exclusion.⁹ Exclusion means no federal program billing at all, which for most practices is a financial death sentence.

Civil Liability

Patients harmed by improper prescribing can pursue malpractice claims. Failing to check the PMP, ignoring red flags for addiction, or prescribing dangerous drug combinations becomes evidence of negligence. Judgments and settlements in controlled substance cases can be substantial, and the reputational damage often outlasts the financial hit.

Defenses If You Are Accused

Prescribers accused of improper prescribing are not without defenses. The most fundamental one is straightforward: proving the prescription was issued for a legitimate medical purpose within a genuine patient-practitioner relationship, supported by thorough documentation of the clinical reasoning.¹ A prescriber who charted the pain assessment, the alternatives considered and rejected, the PMP check, and the rationale for the specific drug and dosage has built a defense in real time, before any accusation was made.

Good faith also carries weight. A prescriber who can show they honestly believed their prescribing was appropriate based on the clinical information available at the time is in a meaningfully different position than one who ignored obvious warning signs. Good faith does not mean the prescriber was right; it means they were not reckless or willfully blind.

Minnesota law also recognizes narrow exceptions for emergency situations where a controlled substance must be administered immediately, and for prescribers participating in approved research or treatment programs operating under modified rules. These exceptions apply to defined circumstances, not to general practice.

1
Minnesota Office of the Revisor of Statutes. 2025 Minnesota Statutes Chapter 152 – Drugs; Controlled Substances
2
Minnesota Department of Human Services. Minnesota Controlled Substance Prescribing Guidelines
3
Minnesota Governor’s Office. Opioid Prescribing Guidelines Overview
4
Centers for Disease Control and Prevention. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022
5
Minnesota Board of Pharmacy. Minnesota Prescription Monitoring Program (MN PMP)
6
DEA Diversion Control Division. Opioid Use Disorder – MATE Act Q&A
7
Federal Register. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
8
Cornell Law School. Minnesota Rules 5605.1100 – Penalties for Noncompliance
9
Office of Inspector General. Background Information